Skip to content
Business Company News, Medical Health Aged Care

Florey biotech spin-out secures seed investment from Curie.Bio

The Florey 2 mins read
LASEREDDu00ae delivers antibodies (light blue) that can bind and drug complex membrane proteins, such as G protein-coupled receptors (purple), in novel ways that enable the discovery of new therapeutics for a range of diseases. Supplied by The Florey

Melbourne-based Alkira Bio, a novel drug discovery platform company, announces seed investment from Curie.Bio. 

Alkira Bio uses its proprietary LASEREDD® technology platform to discover therapeutic antibodies directed against previously out of reach targets, pioneering new possibilities for drug discovery.  

The seed financing from Curie.Bio recognises Alkira Bio’s advanced understanding in targeting complex membrane proteins called G protein-coupled receptors (GPCRs) and the unique capability and potential of the platform.  

Florey researcher turned Alkira Bio’s Chief Executive Officer, Associate Professor Daniel Scott, has studied GPCRs for over two decades to understand how they can be better targeted for drug discovery. 

“Developing therapeutic antibodies that target specific GPCRs has huge potential for creating safe, effective therapeutics to treat conditions with a high unmet medical need,” said Associate Professor Scott. 

“We’re excited to be partnering with Curie.Bio, who recognise the potential of our technology to deliver new therapeutics unlike any existing drug.”  

Curie.Bio’s team of drug hunters and drug makers will co-pilot the drug discovery program, with their model designed to help founders reach value-creating milestones in a rapid and capital efficient manner so that founders retain the economic upside in their companies.  

Florey researcher and Alkira Bio’s Chief Scientific Officer, Dr Chris Draper-Joyce, welcomes the seed investment and partnership.  

“The investment from Curie.Bio will enable us to leverage our antibody discovery platform to tackle important diseases,” said Dr Draper-Joyce. 

“Our ultimate goal is to discover medications that have the potential to transform patient lives, and the Curie.Bio team is the right partner to co-pilot this drug discovery journey.”  

Director of The Florey, Professor Trevor Kilpatrick, added that this was a watershed moment for spin-outs at The Florey. 

“A vital part of bringing important research to global markets is looking at how we commercialise it, and to do that researchers have to think like founders. It’s not always easy, but The Florey has looked to support Alkira Bio at every step to do that,” said Prof Kilpatrick.  

“Now we can look forward to seeing our science having a positive impact on patients in need of new, improved treatments.” 

Key Facts:
  • An innovative drug discovery platform invented by Florey researchers has attracted seed investment from US venture capital. 

  • In partnership with Curie.Bio, Alkira Bio aims to identify antibodies with therapeutic potential  

  • Professor Trevor Kilpatrick said this was a ‘watershed moment’ for spin-outs at The Florey. 

The Florey is Australia’s leading brain research institute with a focus on improving the lives of people with neurological and psychiatric conditions. The Florey’s research missions are centred around dementia, epilepsy, mental health and developing ways to protect and repair the brain. These missions are strengthened by The Florey’s expertise in neurotherapeutics, neuroimaging, synaptic biology and systems neuroscience. With 600 researchers, The Florey is the largest research centre of its kind in the southern hemisphere. 

Find out more about us on our website:  

Contact details:

Kathryn Powley, Media and Communications Manager | 0456 666 271 


More from this category

  • Biotechnology, Medical Health Aged Care
  • 22/07/2024
  • 12:56

Research into psychedelic medicines to treat anxiety wins ANS Illumina Neurogenomics Award 2024

Genomic technologies to discover biological markers, within the blood, that could predict patient response to psychedelic medicines such as psilocybin. MELBOURNE, AUSTRALIA, 22 July 2024 - Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the winner of the annual Australasian Neuroscience Society (ANS) Illumina Neurogenomics Research Award as Dr Andrew Gibbons from the Department of Psychiatry, School of Clinical Sciences at Monash Health. “Psilocybin, a chemical produced by hallucinogenic mushrooms, is a psychedelic medicine that has shown to meaningfully reduce symptoms of generalized anxiety during psychotherapy for patients. However, not all patients respond.…

  • Contains:
  • Industrial Relations, Medical Health Aged Care
  • 22/07/2024
  • 11:12
Australian Nursing and Midwifery Federation (Victorian Branch)

Bolton Clarke nurses and carers to hold stop-work rally – Mon 22 July, 1pm-2pm

WHATANMF Bolton Clarke members two-hour stop work and community rally for fair pay and conditionsACTU Secretary Sally McManus and VTHC Secretary Luke Hilakari will address the rally WHENMonday, 22 July 2024, 1pm-3pm. (Speakers will start 1.05pm sharp) WHEREoutside Bolton Clarke’s Victorian headquarters, 347 Burwood Highway, Forest Hill Bolton Clarke nurses, personal care workers and midwives will stop work for two hours on Monday 22 July to rally for better pay and conditions. For the past 18 months, the Australian Nursing and Midwifery Federation (Victorian Branch) has been negotiating wages and conditions on behalf of about 1700 members working across Bolton…

  • Contains:
  • Medical Health Aged Care
  • 22/07/2024
  • 08:00
Monash University

New guideline to improve reporting in precision medicine globally

Ensuring the best reporting in precision medicine research and ultimately the best outcome for patients is the goal of a new international guideline, the first of its kind. The guideline is produced by an international consortium, chaired by Professor Paul Franks from Lund University in Sweden and co-chaired by Dr Siew Lim from Monash University’s Eastern Health Clinical School. Precision medicine, which is designed specifically for each individual patient and their disease, maximises their chances of a favourable result.Until now there has been no standardised guideline for reporting research on precision medicine, which tailors treatment to unique aspects of each…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.